Enalapril for severe congestive heart failure. A double-blind study.

  title={Enalapril for severe congestive heart failure. A double-blind study.},
  author={G. Jennings and H S Kiat and Larry Lee Nelson and Michael J. Kelly and Victor Kalff and J Johns},
  journal={The Medical journal of Australia},
  volume={141 11},
The effects of the new, orally administered converting-enzyme inhibitor, enalapril (MK-421), were studied in 12 ambulatory patients with severe cardiac failure who were also receiving digoxin and diuretic agents. The study was double-blind, parallel, placebo-controlled and randomized. The clinical characteristics and pretreatment exercise performance were similar in the two groups of patients. All vasodilator drugs had been withdrawn two weeks before the start of the trial. At 12 weeks, the… CONTINUE READING